Arca
Skip to content

Warning Letter to Fagron, Inc

Drugs. See Fagron's company page.

On Jun 13, 2019, FDA's CDER sent Fagron, Inc a warning letter.

  • Letter date: Jun 13, 2019
  • Issued by: CDER
  • Closeout: —

The Letter

As posted on FDA.gov ↗; cited 21 CFR sections link to their page.

Dear Mr. Padilla:

The Food and Drug Administration has completed evaluation of your firm’s corrective actions in response to our Warning Letter [Case# 545906] dated August 29, 2018. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely, /S/ Nicholas F. Lyons Compliance Director Division of Pharmaceutical Quality Operations III

cc: Teresa Fiedler, President Fagron North America Fagron Inc. 2400 Pilot Knob Road St. Paul, MN 55120

The Firm's Other Letters

Same company or the same FDA site, newest first
  • Fagron BVMay 12, 2026 · CDER · Aseptic processing, Sterility assurance

Record

Recipient
Rafael Padilla
FDA site ID (FEI)
—
Cited
—

Tags are assigned by Arca from the letter's text. A closeout letter means FDA found the firm's corrections adequate; no closeout does not mean the issues are unresolved. FDA warning letters

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.